| Literature DB >> 15708298 |
Deborah A Yurgelun-Todd1, Joseph T Coyle, Staci A Gruber, Perry F Renshaw, Marisa M Silveri, Edward Amico, Bruce Cohen, Donald C Goff.
Abstract
The objective of the present study was to examine patterns of cortical activation underlying D-cycloserine's therapeutic efficacy in schizophrenic patients using functional magnetic resonance imaging (fMRI). We measured frontal and temporal lobe activation following a word fluency task in 12 subjects meeting DSM-IV criteria for schizophrenia at baseline and after 8 weeks of supervised treatment, using a double-blind, placebo-controlled design. Half of the patients received D-cycloserine (n = 6) as a supplement to their conventional neuroleptic treatment while the other half (n = 6) was augmented with placebo. Patients receiving D-cycloserine, but not placebo, demonstrated a significant increase in temporal lobe activation. This increased activation was significantly associated with a reduction in negative symptoms. These results suggest that the addition of D-cycloserine to conventional neuroleptics may improve negative symptoms through enhanced temporal lobe function.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15708298 DOI: 10.1016/j.pscychresns.2004.11.006
Source DB: PubMed Journal: Psychiatry Res ISSN: 0165-1781 Impact factor: 3.222